Updated on 22 August 2012
The AHP kit has analytical sensitivity and specificity of 100 percent. It has clinical sensitivity and specificity of 100 percent. Around 110 specimen, who were detected for HIV, were confirmed to carry HIV antibodies (PPV=100 percent ). AHP kit has very high diagnostic accuracy with high precision and reproducibility. The AHP Kit has neither showed any cross reaction with HIV negative sera, nor detected any of unrelated microbes, namely herpes simplex virus, Chlamydia trachomatis, Neisseria gonorrhoea, H1N1 virus, influenza A virus, cytomegalo virus, hepatitis B virus and John Cunningham/BK (JC/BK) viruses.
Twenty individuals, who were HIV negative by PCR, appeaqred to be positive for HIV antibodies follwoing the use of AHP kit. It was confirmed using the patients' history that all 20 individuals were in highly active antiretroviral therapy (HAART) scheme sponsored by WHO-United Nation. Therefore, PCR ‘not detected' does not always suggest the absence of HIV antibodies. AHP's test kit is ideal for rapid screening of HIV suspected individuals.
Challenge 2: Multiple drivers shape the fate of HIV diagnostics and AIDS patient monitoring
AHP kits are used for initial screening of blood for HIV antibodies followed by confirmation tests using Abbott's ARCHITECT platform. Simultaneously, specimens undergo HIV viral load test (quantitative PCR) to measure the status of immune system in HIV infected individuals. These multi-technological approaches have significantly increased the efficiency of HIV diagnostics, monitoring, progression and also to predict the risk of complications and debilitating infections in the future. Ideally, the CD4 count should increase or stabilize in response to effective anti-HIV therapy. Continuous decline of CD4 count in relation to CD8 cells over several months is the indication of ineffectiveness of anti-retroviral treatment and/or initiating prophylactic treatment for opportunistic infections such as Pneumocystis pneumonia (PCP) or Mycobacterium avium infection.